Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
This study is currently recruiting participants.
Verified August 2013
by Millennium Pharmaceuticals, Inc.
Study NCT01578499 Information provided by Millennium Pharmaceuticals, Inc.
First Received on March 27, 2012. Last Updated on August 18, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cutaneous T-Cell Lymphoma
Additional conditions recognized in this trial
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Primary Cutaneous Anaplastic Large Cell
Lymphoma, T-Cell, Cutaneous
More general conditions related to this trial
Immune System Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
Methotrexate or Bexarotene
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Abortifacient Agents, Nonsteroidal
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Physiological Effects of Drugs
Reproductive Control Agents
Sponsors listed in this trial
Millennium Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers